No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PMVP PMV Pharmaceuticals
- 1.610
- -0.040-2.42%
Close Jun 18 16:00 ET
- 1.690
- +0.080+4.96%
Post 17:34 ET
82.82MMarket Cap-1219P/E (TTM)
1.660High1.605Low256.62KVolume1.650Open1.650Pre Close415.88KTurnover0.63%Turnover RatioLossP/E (Static)51.44MShares9.72052wk High0.39P/B65.21MFloat Cap1.17552wk Low--Dividend TTM40.50MShs Float63.220Historical High--Div YieldTTM3.33%Amplitude1.175Historical Low1.620Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June
PRINCETON, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting
Buy Rating on PMV Pharmaceuticals: Strategic Partnerships and Promising Clinical Pipeline Underpin Positive Outlook
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective P53 Y220C Reactivator
Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, "PMV Pharma")) today announced a partnership to develop Foundation Medicine's tissue-based comprehensive genomic profiling test,
Analysts Offer Insights on Healthcare Companies: PMV Pharmaceuticals (PMVP) and Phathom Pharmaceuticals (PHAT)
PMV Pharmaceuticals Initiated at Buy by Craig-Hallum
PMV Pharmaceuticals Initiated at Buy by Craig-Hallum
Express News | Craig-Hallum Initiates Coverage On PMV Pharma With Buy Rating, Announces Price Target of $6
Comments
$PMV Pharmaceuticals(PMVP.US$ i am so in on this.
1
1
$PMV Pharmaceuticals(PMVP.US$ PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation
3
3
Gainer:
• $Red Robin(RRGB.US$ +13.8% (In reaction to earnings)
• $PMV Pharmaceuticals(PMVP.US$ +11.2% (ASCO-related announcement)
• $Sumo Logic(SUMO.US$ +10.8% (In reaction to earnings)
• $Adicet Bio(ACET.US$ +9.6% (ASCO-related announcement)
• $Dell Technologies(DELL.US$ +9.6% (In reaction to earnings)
• $ImmunoGen(IMGN.US$ +8.7% (ASCO-related announcement)
• $Ulta Beauty(ULTA.US$ +7.9% (In reaction to earnings)
• $Zymergen(ZY.US$ +7.8% (to...
• $Red Robin(RRGB.US$ +13.8% (In reaction to earnings)
• $PMV Pharmaceuticals(PMVP.US$ +11.2% (ASCO-related announcement)
• $Sumo Logic(SUMO.US$ +10.8% (In reaction to earnings)
• $Adicet Bio(ACET.US$ +9.6% (ASCO-related announcement)
• $Dell Technologies(DELL.US$ +9.6% (In reaction to earnings)
• $ImmunoGen(IMGN.US$ +8.7% (ASCO-related announcement)
• $Ulta Beauty(ULTA.US$ +7.9% (In reaction to earnings)
• $Zymergen(ZY.US$ +7.8% (to...
11
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg